New drug combo aims to boost CAR-T success in hard-to-treat lymphoma

NCT ID NCT07341191

Recruiting now Disease control Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 4 times

Summary

This study tests whether adding two oral medications (sonrotoclax and zanubrutinib) to standard CAR-T cell therapy can improve treatment results for people with mantle cell lymphoma that has come back or not responded to prior treatment. About 40 adults who are already eligible for CAR-T therapy will take these drugs alongside their usual care. The goal is to see if this combination leads to better cancer control and longer survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Locations

BCCA - Vancouver
RECRUITING

Vancouver, British Columbia, V5Z 4E6, Canada
Cross Cancer Institute
NOT_YET_RECRUITING

Edmonton, Alberta, T6G 1Z2, Canada
University Health Network
RECRUITING

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.